Literature DB >> 15201619

Chronic stent recoil plays an important role in restenosis of the right coronary ostium.

Taro Tsunoda1, Masato Nakamura, Masamichi Wada, Naoki Ito, Yoko Kitagawa, Masanori Shiba, Suguru Yajima, Raisuke Iijima, Rintaro Nakajima, Masato Yamamoto, Takuro Takagi, Takashi Yoshitama, Hitoshi Anzai, Takahiro Nishida, Tetsu Yamaguchi.   

Abstract

OBJECTIVE: The efficacy of coronary stenting of aorto-ostial atherosclerotic lesions is still unclear. We investigated the frequency and mechanism of stent restenosis at this particular lesion.
METHODS: Fifty-five consecutive patients with 64 native aorto-ostial lesions in the right coronary artery (RCA, n = 38) and the left main trunk (LM, n = 26) were treated by conventional stenting. Determinants of angiographic restenosis were established. The mechanism of stent restenosis was evaluated using post-stenting and follow-up intravascular ultrasound (IVUS) findings.
RESULTS: Restenosis was more frequent in the RCA than in the LM (50% compared with 19%, P < 0.03) and determinants included diabetes mellitus (63% compared with 21%, P < 0.03), calcium deposition (58% compared with 5%, P < 0.003), smaller stent cross-sectional area (SA) (as demonstrated by post-stenting IVUS studies, 8.1 +/- 1.4 mm compared with 10.2 +/- 2.2 mm, P < 0.01), larger plaque burden (64 +/- 6% compared with 57 +/- 8%, P < 0.03) and less circular expansion at the aorto-coronary junction. Serial IVUS examination was performed in 11 patients with restenosis of the right coronary ostium. The mean reduction in the SA was 21% at the aorto-coronary junction (6.4 +/- 1.9 mm, P < 0.003), whereas the SA at the distal edge was unchanged. Thirty-three per cent of late luminal loss was due to chronic stent recoil.
CONCLUSION: These findings suggest that stenosis of the right coronary ostium is a high-risk lesion for stent restenosis. In addition to excessive intimal growth, chronic stent recoil might be an important etiologic factor at this particular location. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2004        PMID: 15201619     DOI: 10.1097/00019501-200402000-00006

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  6 in total

1.  Preventable effects of bare-metal stent on restenosis after everolimus-eluting stent deployment.

Authors:  Akihiro Shirakabe; Masamichi Takano; Masanori Yamamoto; Osamu Kurihara; Nobuaki Kobayashi; Masato Matsushita; Masafumi Tsurumi; Hirotake Okazaki; Noritake Hata; Wataru Shimizu
Journal:  Heart Vessels       Date:  2014-10-21       Impact factor: 2.037

Review 2.  [Percutaneus coronary interventions for ostial lesions].

Authors:  J Wöhrle; S Markovic
Journal:  Herz       Date:  2016-11       Impact factor: 1.443

3.  Clinical impact of the gap-angle ratio in patients with ostial lesions of the right coronary artery undergoing percutaneous coronary intervention.

Authors:  Koichi Ohashi; Daisuke Abe; Norihiro Kuroki; Takao Yuba; Kou Suzuki
Journal:  Heart Vessels       Date:  2019-04-26       Impact factor: 2.037

4.  Endovascular treatment of the vertebral artery origin stenosis by using the closed-cell, self-expandable Carotid Wallstent.

Authors:  Jun-Kyeung Ko; Chang-Hwa Choi; Lee Hwangbo; Hie-Bum Suh; Tae-Hong Lee; Han-Jin Cho; Sang-Min Sung
Journal:  Interv Neuroradiol       Date:  2020-06-20       Impact factor: 1.610

5.  Comparison of bare-metal stents and drug-eluting stents in coronary ostial lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry).

Authors:  Samip Vasaiwala; Helen Vlachos; Faith Selzer; Oscar Marroquin; Suresh Mulukutla; J Dawn Abbott; David O Williams
Journal:  Am J Cardiol       Date:  2012-07-03       Impact factor: 2.778

6.  Clinical Outcomes after Additional Dynamic Renal® Stent Implantation for Stent Recoil in Ostial Coronary Lesions.

Authors:  Bachir Abdulrahman; Kambis Mashayekhi; Péter Tajti; Miroslaw Ferenc; Christian Marc Valina; Willibald Hochholzer; Franz-Josef Neumann; Thomas Georg Nührenberg
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.